

1 **Mitochondrial haplogroups in association study with**
2 **onset and progression of diabetic retinopathy**

3 **Veronika Medova,^{1,2} Andrea Soltysova,^{1,2} Nikola Pribulova,¹ Ludevit Kadasi,^{1,2}**
4 **Andrej Ficek^{1*}**

5 ¹Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, Ilkovicova 6 Bratislava,
6 842 15 Slovakia

7

8 ²Institute for Clinical and Translational Research, Biomedical Research Centre, Slovak Academy of Sciences,
9 Dubravska cesta 9, 845 05 Bratislava, Slovakia

10

11 ***Corresponding author**

12

13 **Word count:** 3247 words (Title page and Abstract excluded)

14 **Funding Information:** The authors acknowledge the funding provided by Research and
15 Development Operational Programme ITMS 26240120038, 2013/4.1/04-SORO.

16 **Commercial relationships disclosures:** None

17

18

19

20

21

22

23

24

25 **Abstract**

26 **Purpose**

27 Diabetic retinopathy (DR) is the most frequent microvascular complication in patients with
28 diabetic mellitus (DM). Excessive formation of reactive oxygen species and mitochondrial
29 dysfunction in retina suggest the possible role of mitochondrial variability on DR. We aimed
30 to test for association of mtDNA haplogroups with occurrence and progression of DR in 361
31 Slovak diabetic patients.

32 **Methods**

33 3897 diabetic patients were included in the project in which clinical ocular examination was
34 carried out for all participants. 361 patients, based on the presence of DR (G-RET - DR
35 present within first 7 years since DM diagnosed, G-CON – no signs of DR after 17 years of
36 DM) were selected for mtDNA haplotype determination by HV1 region sequencing to test for
37 association with DR occurrence and progression.

38 **Results**

39 Based on clinical examination in 3897 patients we observed strong association of retinopathy
40 with type 1 DM ($p=0.00001$) and association with type 2 DM when development of
41 retinopathy within first 7 years of diabetes was considered ($p=0.005$). While no difference of
42 DR occurrence was observed between males and females, strong association of DR with
43 males was identified in G-RET group ($p=0.0001$). While mitochondrial haplogroup
44 distribution did not significantly differ between G-RET and G-CON groups, indication of
45 association of haplogroup HV ($p=0,044$) and M ($p=0,033$) with severity of DR was observed.
46 This observation need to be replicated in further studies due to small sample size, however.

47 **Conclusions**

48 Mitochondrial haplogroups HV and M are supposed to be implicated in DR progression with
49 further studies needed.

50

51 **Keywords:** diabetic retinopathy, mtDNA haplogroups, mitochondria

52

53 **Introduction**

54 Diabetic retinopathy (DR) is one of the most common complication of *diabetes*
55 *mellitus* (DM) and is leading cause of vision loss in diabetic patients and working adults in
56 developed countries. Prevalence of any type of diabetic retinopathy, vision threatening
57 progressive forms of proliferative diabetic retinopathy (PDR) and diabetic macular edema
58 (DME) in diabetic patients is as high as 34,6%, 7,0% and 6,8%, respectively.¹

59 Increased circulation of blood glucose through vessels during diabetes results in micro
60 and macro vascular damage,² which is amplified by hypertension and dyslipidaemia as risk
61 factors associated with arise and progression of the disease.^{3,4} Multiple biochemical pathways
62 and cellular mechanisms might explain diabetes driven complications, with some of them
63 being studied the most like polyol pathway flux, increased advanced glycation end-products
64 (AGEs) formation, protein kinase C activation signaling pathways or increased oxidative
65 stress, reviewed in Sharma et al., (2019).⁵ Ongoing inflammation, vascular occlusion and
66 oxidative stress upregulate factors like vascular endothelial growth factor (VEGF), insulin-
67 like growth factor (IGF), angiopoietins (Ang-2), tumor necrosis factor (TNF) and lead to
68 progression of diabetic retinopathy.¹ Hyperglycaemic milieu creates conditions for increased
69 glucose auto-oxidation and/or initiation of metabolic abnormalities which leads to formation
70 of reactive oxygen species (ROS) thus creating excessive free radicals environment which is
71 supposed to have the central role in the pathogenesis of retinopathy.⁶

72 Mitochondria is a significant source of reactive oxygen species which production is
73 elevated in hyperglycaemia and resulting in damage to macromolecules and mitochondria
74 dysfunction.^{7,8} Genetic variability of mitochondrial DNA, driven by higher mutation rate in

75 mitochondria and defined in distinct matrilinear mtDNA haplogroups, is assumed to be
76 phenotypically mostly neutral, however there have been several studies that shown
77 association of certain mitochondrial haplogroups with various complex disorders.^{9,10}
78 Considering the role of mitochondria in diabetic retinopathy there have been published studies
79 such as Bergman et.al. (2017), who described connection of haplogroup H to severity, but not
80 prevalence of diabetic retinopathy, or Mitchell et al. (2017), who stated modifying effect of
81 mitochondrial haplogroups U and UK on proliferative diabetic retinopathy in patients with
82 type 2 diabetes.^{11,12} On the other hand, one of the latest studies declared, that haplogroup H
83 have no association with diabetic retinopathy in large Caucasian sample.¹³

84 The opposite findings of these studies led us to test the distribution of mtDNA
85 haplogroups, based on HV1 region sequencing, in 361 Slovak patients with type 1 (T1DM)
86 and type 2 (T2DM) diabetes considering the type of diabetes, sex, disease duration and degree
87 of retinal damage.

88

89 **Material and methods**

90 **Patient samples**

91 During DIARET project (ITMS: 26240120038) 3897 diabetic patients' samples were
92 collected and deposited in DNA bank with deidentified clinical data. Of these patients, two
93 smaller clinically distant groups of patients were selected for further genetic study based on
94 retinopathy occurrence in relation to diabetes duration. The first group (G-RET) consisted of
95 129 patients with diabetic retinopathy developed in less than seven years after DM diagnosis,
96 while the second group (G-CON) consisted of 232 patients with diabetes duration for at least
97 17 years but no signs of diabetic retinopathy so far.

98 The ophthalmological examination was performed at the time of the project for all
99 patients enrolled in the study. Considering the degree of retinopathy progression, NPDR was

100 considered as mild when one or both eyes were affected with presence of microaneurysm
101 and/or retinal hemorrhages, while severe NPDR was considered when presence of more than
102 2 indicators (microaneurysm, hemorrhages and soft exudates, extensive intra-retinal
103 hemorrhages in 4 quadrants, intra-retinal microvascular abnormalities and/or phlebitis in more
104 than 1 quadrants) were present at least on one eye. PDR and DME were considered as severe
105 complications.

106 The study was conducted according to the principles outlined in the Declaration of
107 Helsinki and written informed consent was obtained from all patients.

108

109 **Mitochondrial haplogroup identification**

110 Mitochondrial hypervariable region I was amplified using HOT FIREPol® DNA
111 Polymerase (Solis BioDyne, Estonia) and specific primers (upon request). Sequencing
112 analysis of amplicons was performed using BigDye™ Terminator v3.1 Cycle Sequencing Kit
113 and fragments were analysed using ABI Prism 3130xl Genetic Analyzer (Life Technologies,
114 USA). Alignment to the reference sequence (NCBI NC 012920) and variants identification
115 allowed for haplogroup assignment using Haplogrep2 classification tool.¹⁴

116

117 **Statistical analysis**

118 Chi-square test was used to analyze characteristics of the whole set of 3897 diabetic
119 patients considering sex, age, type of diabetes in relation to retinopathy progression and
120 diabetes duration. Chi-square test was applied also for comparisons of mitochondrial
121 haplotypes and/or haplogroups distribution between selected two clinically distant groups of
122 patients.

123

124 **Results**

125 3897 diabetic patients (53,3% women) of slovak (93%), hungarian (5.9%), czech
126 (0.49%), and roma (0.33%) nationality with deidentified clinical data were included in the
127 project. 10,09% of patients suffered from type 1 diabetes with the average age of diabetes
128 onset and duration of disease at the time of the study 25.9/14.78 years, while in type 2
129 diabetes patients it was 53.19/8.47 years, respectively.

130 For the subsequent genetic analysis we selected two groups of patients, denoted G-
131 RET and G-CON, depending on the presence of DR in relation to the diabetes duration. 129
132 (33,3% women) patients in G-RET group were characterized with maximum of 7 years from
133 DM diagnosis (average 4.29y) and presence of retinopathy, while 232 (57,14% women)
134 patients in G-CON group suffered from diabetes for minimum of 17 years (average 22,5y)
135 without any clinical signs of DR (Table 1).

136 In the whole group of patients diabetic retinopathy was found to be significantly more
137 often in T1DM patients ($p < 0.00001$), and with reverse association observed after G-RET/G-
138 CON selection ($p < 0.0005$). Diabetic retinopathy was not associated with gender in all
139 patients, however selection based on disease duration and retinopathy prevalence (G-RET/G-
140 CON) showed diabetic retinopathy to be present more often in males ($p < 0.0001$) (Table 1).

141

142

143

144

145

146

147


148

149 **Table 1. Prevalence of diabetic retinopathy in relation to DM diagnosis duration and**
 150 **gender**

All patients N (%)						
	T1DM	T2DM	p- value	Female	Male	p- value
DR	128 (34.87)	529 (16.2)	0.00001	363 (17.46)	355 (19.53)	0.096
Without DR	239 (65.13)	2738 (83.8)		1716 (82.54)	1463 (80.47)	
Selected groups of patients depending on extreme values						
G-RET	9 (15)	120 (39.87)	0.0005	43 (24.57)	87 (46.77)	0.0001
G-CON	51 (85)	181 (60.13)		132 (75.43)	99 (53.23)	

151

152 Based on observed mitochondrial HV1 sequence variation in 361 analyzed patients we
 153 identified 161 haplotypes belonging to 56 subhaplogroups (Fig. 1). Due to low sample
 154 numbers in groups we combined identified haplotypes into 10 common subhaplogroups. The
 155 most common haplogroup H allowed us to analyze samples of this group in separate H1
 156 (8.86%), H2 (18.56%), HV (8.31%) and other H (15.24%) subhaplogroups. The rest of
 157 haplotypes belonged to subhaplogroup UK (19.95%), T (9.97%), J (7.2%), joined N-others (I,
 158 W, X, Y, N) (6.65%), M (3.32%) and R-others (R8, R9, R14) (1.94%). Distribution of these
 159 10 haplogroups did not show any statistically significant (chi-square) difference between G-
 160 RET/G-CON groups (Fig.2A).



161

162

163

164

165

Figure 1. Occurrence of 56 mitochondrial subhaplogroups identified in 361 DM patients divided into two groups: G-RET - patients with retinopathy within 7y of DM, and G-CON - control group of DM without retinopathy after 17y of DM.

166

167

168

169

Since we observed association of sex with prevalence of the retinopathy in G-RET/G-CON groups, we tested for the association of mitochondrial haplogroups with DR status within individual sex groups separately. None of analyzed haplogroups was significantly associated with presence of DR complications in relation to sex.

170

171

172


173

174

175

176

Further, we tested haplogroup distribution for association in relation to the severity of DR. Patients with DR were divided into 2 groups based on severity of retinopathy, considering clinical presentation of retinopathy according to clinical ocular examination at the time of the study described in material and methods section. Similar distribution of haplogroups with no statistical difference in both (severe, mild) groups were observed, except for HV and M haplogroups ($p=0,044$, and $p=0,033$, respectively) which indicate the possible association of HV and M haplogroups with DM progression (Figure 2B).



177

178

179

180

181

182

183

184 **Discussion**

185

186

187

188

189

Figure 2. Proportion of observed haplogroups in retinopathy G-RET (black) and control - without retinopathy G-CON (hatched black) groups of DM patients (A), and proportion of observed haplogroups in G-RET patients divided into mild (black) and severe (hatched black) DR subgroups (B). P values from chi-square test are presented, with significant p values bolded.

Diabetic retinopathy is one of the most common causes of acquired blindness in middle age population with prevalence to vary between 10-61% in patients with known diabetes and between 1.5-31% in newly diagnosed diabetes in various populations.¹⁵ Sex-gender differences in the onset of diabetic complications, such as DR, seem to be independent risk factor according some studies, while others showed no statistically significant

190 difference.¹⁶⁻¹⁸ The disease heterogeneity, selection criteria, number of patients analyzed, and
191 ethnicity in various studies may be responsible for such conflicting observations. Prevalence of
192 DR in group of 3897 patients present in this study was 18.4% with observed difference
193 between sexes only when considering the onset of DR with respect to the duration of diabetes.
194 The presence of DR in male and female patients did not reveal significant difference in all
195 patients (Table 1), however strong association of DR with males was seen in patients with
196 retinopathy diagnosed within 7 years since the DM onset ($p=0.0001$).

197 Various studies considered the prevalence of diabetic retinopathy in relation to the
198 type of diabetes.¹⁹ In our observation, diabetic retinopathy was found to be present
199 significantly more often in T1DM (34.87%) patients compared to T2DM (16.2%) when
200 compared in all 3897 patients ($p<0.00001$), which is in agreement with other studies, such as
201 Matuszewski et al. (2020).²⁰ Interestingly, there was seen a strong reverse association after G-
202 RET/G-CON selection ($p=0.0005$), showing that diabetic retinopathy in T1DM usually do not
203 develop within first years of DM diagnosis, but later in decades.²¹

204 As a causal link between high glucose levels and metabolic abnormalities observed in
205 DR are considered ROS, which originate at higher rate in elevated glucose environment.
206 Damage to the retinal mitochondria during ROS driven pathogenesis of DR leads to decreased
207 copy number of mtDNA, transcription of mtDNA encoded genes, and subsequent
208 mitochondrial dysfunction.²² While ROS are constantly produced by mitochondria and
209 mitochondrial dysfunction is seen in DR pathogenesis, mitochondrial genetic variation
210 became the subject for possible implication in the onset and progression of DR. Even though
211 the association of mitochondrial haplogroups to various disorders has been studied for long
212 time and to date many studies observed association of different haplogroups as risk or
213 protective factors in pathogenesis of different diseases, studies focused on the association of
214 mitochondrial haplogroups to the diabetic retinopathy are rare. Several studies linked diabetic

215 retinopathy with one or other haplogroup but the results are inconclusive. While Kofler et al.
216 (2009) observed association of T haplogroup with CAD and DR in T2DM patients, Achilli et
217 al. (2011) identified relationship between DR in T2DM and haplogroup H.^{23,24}

218 In this study we attempt to assess the possible association of mitochondrial
219 haplogroups to the onset and progression of DR in analysis of two clinically distinct groups of
220 DM patients. Mitochondrial haplotypes were determined based on HV1 region sequences in
221 129 DM patients with DR developed within 7 years since DM diagnosis (G-RET group), and
222 232 DM patients without any signs of DR despite of at least 17 years of DM duration (G-
223 CON group). In these 361 patients we identified 161 haplotypes belonging to 56
224 subhaplogroups. Due to low numbers in these subhaplogroups, samples were combined into
225 larger, common haplogroups. As expected the most represented haplogroup was haplogroup
226 H (51,97%), the most common haplogroup in Europe, which was identified in 51.16% of G-
227 RET and 50.86% of G-CON group. This allow us to analyze samples belonging to H
228 haplogroup in separate H1, H2, and HV sub-haplogroups. The rest of haplotypes belonged to
229 other H, UK, T, J, N-other (I, W, X, Y, N), M and R-other (R8, R9, R14) haplogroups. None
230 of haplogroups showed significant difference in distribution between the two groups, not even
231 after stratifying samples by sex. These findings are in agreement to those in study by Liu et al.
232 (2019) which was carried out on 2935 Caucasian DR patients with neither of haplogroups H1,
233 H2, UK, K or JT being associated with any type of DR (NPDR, PDR or DME).¹³

234 In the study by Bregman et al. (2017) severity but not prevalence of the disease was
235 associated with mitochondrial haplogroups when haplogroup H was associated to be a risk
236 factor for and haplogroup UK to be protective against proliferative diabetic retinopathy (PDR)
237 among Caucasian DR patients.¹¹ This study characterized connection between mitochondrial
238 haplogroups, duration of diabetes and HbA_{1C}, and identified haplogroups as risk factors for
239 proliferative DR. The assumption is that in cells of patients with haplogroup H there is

240 increased ROS production as result of high glucose level and / or reduced ability to manage
241 elevated oxidation stress leading to vascular damage in retina and damage to the
242 mitochondria. These effects could be worsen by long duration of diabetes but also due to
243 metabolic memory phenomenon. This phenomenon describes the fact that mitochondrial
244 damage could progress even after re-institution of good glycaemic control. Considering
245 mentioned factors it can be assumed that patients with haplogroup H may be more sensitive to
246 the effect of prolonged diabetes and poor glycaemic control.^{12,25} To test the association of
247 mitochondrial haplogroups with DR severity, we stratify DR patients into two groups based
248 on severity of clinical retinal findings to mild and severe according to Alghadyan 2011.²⁶
249 Clinical ocular examination was carried out at the time of the study so we can exclude various
250 evaluation criteria changing over time. Similar distribution of all haplogroups in (severe,
251 mild) DR groups of patients were observed, except for HV and M haplogroups, for which
252 indication of weak association predetermines HV as protective (p=0,044) and M as risk factor
253 for severe retinopathy (p=0,033). However, we must point out the limitation of this indication
254 that lie in the small sample size of patients in groups: HV (12 patients out of 78 in mild and 0
255 patients out of 51 in severe DR group) and M (0 out of 78 in mild and 6 out of 51 in severe
256 DR group). As mentioned before by other studies, the problem with small numbers of patients
257 identified for some haplogroups greatly limits the approach and depends on demographic
258 factors, distribution of haplogroups, study design and sample size. Nevertheless, these
259 observations might be considered and tested in further studies.

260

261 **Acknowledgment**

262 The authors acknowledge the funding provided by Research and Development
263 Operational Programme ITMS 26240120038, 2013/4.1/04-SORO.

264

265 **References**


266


- 267 1. Safi SZ, Qvist R, Kumar S, Batumalaie K and Ismail ISB. Molecular mechanisms of
268 diabetic retinopathy, general preventive strategies, and novel therapeutic targets.
269 *Biomed Res Int.* 2014; 2014: 801269
- 270 2. Sarhangi N, Khatami F, Keshtkar A, Heshmat R, Atlasi R, Mohammadamoli M. The
271 Role of Mitochondrial DNA (mtDNA) in the Development of Diabetic Retinopathy
272 (DR): A Systematic Review. *Med Hypothesis Discov Innov Ophthalmol.* 2017; 6 (2):
273 30–38.
- 274 3. Kowluru RA, Mishra M. Contribution of epigenetics in diabetic retinopathy. *Sci China*
275 *Life Sci.* 2015; 58:556–563.
- 276 4. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet.* 2010;
277 10;376(9735):124-36.
- 278 5. Sharma A, Valle ML, Beveridge C, Liu Y, Sharma S. Unraveling the role of genetics in
279 the pathogenesis of diabetic retinopathy. *Eye (Lond).* 2019; 33(4): 534–541.
- 280 6. Kowluru RA. Mitochondrial stability in diabetic retinopathy: Lessons learned from
281 epigenetics. *Diabetes.* 2019; 68: 241–247.
- 282 7. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. *Exp Diabetes Res.*
283 2007; 2007: 43603.
- 284 8. Stuart JA, Brown MF. Mitochondrial DNA maintenance and bioenergetics. *Biochim*
285 *Biophys Acta.* 2006;1757(2):79-89
- 286 9. Hahn A, Zuryn S. Mitochondrial genome (mtDNA) mutations that generate reactive
287 oxygen species. *Antioxidants (Basel).* 2019;8(9):392
- 288 10. Marom S, Friger M, Mishmar D. MtDNA meta-analysis reveals both phenotype
289 specificity and allele heterogeneity: a model for differential association. *Sci Rep.*

- 290 2017;7:43449
- 291 11. Bregman JA, Herren DJ, Estopinal CB, Chocron IM, Harlow PA, Warden C, Brantley
292 MA Jr., Samuels DC. Mitochondrial haplogroups affect severity but not prevalence of
293 diabetic retinopathy. *Invest Ophthalmol Vis Sci.* 2017; 58(2):1346-1351.
- 294 12. Mitchell SL, Neiningner AC, Bruce CN, Chocron IM, Bregman JA, Estopinal CB,
295 Muhammad A, Umfress AC, Jarrell KL, Warden C, Harlow PA, Wellons M, Samuels
296 DC, Brantley MA Jr. Mitochondrial haplogroups modify the effect of diabetes duration
297 and HbA1c on proliferative diabetic retinopathy risk in patients with type 2 diabetes.
298 *Invest Ophthalmol Vis Sci.* 2017; 58(14):6481-6488.
- 299 13. Liu E, Kaidonis G, Gillies MC, Abhary S, Essex RW, Chang JH, Pal B, Daniell M,
300 Lake S, Gilhotra J, Petrovsky N., Hewitt AW, Jenkins A, Lamoureux EL, Gleadle JM,
301 Burdon KP, Craig JE. Mitochondrial haplogroups are not associated with diabetic
302 retinopathy in a large Australian and British Caucasian sample. *Sci Rep.* 2019;9(1):612.
- 303 14. Weissensteiner H, Pacher D, Kloss-Brandstätter A, Forer L, Specht G, Bandelt HJ,
304 Kronenberg F, Salas A, Schönherr S. HaploGrep 2: mitochondrial haplogroup
305 classification in the era of high-throughput sequencing. *Nucleic Acids Res.*
306 2016;44(W1):W58-63.
- 307 15. Ruta LM, Magliano DJ, Lemesurier R, Taylor HR, Zimmet PZ, Shaw JE. Prevalence of
308 diabetic retinopathy in Type 2 diabetes in developing and developed countries. *Diabet*
309 *Med.* 2013;30(4):387-98.
- 310 16. Cui Y, Zhang M, Zhang L, Zhang L, Kuang J, Zhang G, Liu Q, Guo H, Meng Q.
311 Prevalence and risk factors for diabetic retinopathy in a cross-sectional population-
312 based study from rural southern China: Dongguan Eye Study. *BMJ Open.* 2019; 9(9):
313 e023586.
- 314 17. Yin L, Zhang D, Ren Q, Su X, Sun Z. Prevalence and risk factors of diabetic

- 315 retinopathy in diabetic patients: A community based cross-sectional study. *Medicine*
316 (*Baltimore*). 2020;99(9):e19236.
- 317 18. Ozawa GY, Bearse MA Jr, Adams AJ. Male-female differences in diabetic
318 retinopathy? *Curr Eye Res*. 2015;40(2):234-46.
- 319 19. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ,
320 Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T,
321 Klein BEK, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M,
322 Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ,
323 Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY, Meta-Analysis for
324 Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of
325 diabetic retinopathy. *Diabetes Care*. 2012;35(3):556-64.
- 326 20. Matuszewski W, Baranowska-Jurkun A, Stefanowicz-Rutkowska MM, Modzelewski
327 R, Pieczyński J, Bandurska-Stankiewicz E. Prevalence of Diabetic Retinopathy in Type
328 1 and Type 2 Diabetes Mellitus Patients in North-East Poland. *Medicina (Kaunas)*.
329 2020; 56(4): 164.
- 330 21. Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O'Neal DN, Januszewski AS.
331 Biomarkers in Diabetic Retinopathy. *Rev Diabet Stud*. 2015; 12(1-2): 159–195.
- 332 22. Massaad CA, Klann E. Reactive Oxygen Species in the Regulation of Synaptic
333 Plasticity and Memory. *Antioxid Redox Signal*. 2011; 14(10): 2013–2054.
- 334 23. Kofler B, Mueller EE, Eder W, Stanger O, Maier R, Weger M, Haas A, Winker R,
335 Schmut O, Paulweber B, Iglseider B, Renner W, Wiesbauer M, Aigner I, Santic D,
336 Zimmermann FA, Mayr JA, Sperl W. Mitochondrial DNA haplogroup T is associated
337 with coronary artery disease and diabetic retinopathy: a case control study. *BMC Med*
338 *Genet*. 2009;10:35.

- 339 24. Achilli A, Olivieri A, Pala M, Kashani BH, Carossa V, Perego UA, Gandini F, Santoro
340 A, Battaglia V, Grugni V, Lancioni H, Sirolla C, Bonfigli AR, Cormio A, Boemi M,
341 Testa I, Semino O, Ceriello A, Spazzafumo L, Gadaleta MN, Marra M, Testa R,
342 Franceschi C, Torroni A. Mitochondrial DNA backgrounds might modulate diabetes
343 complications rather than T2DM as a whole. *PLoS One*. 2011;6(6):e21029.
- 344 25. Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. Role of mitochondrial
345 DNA damage in the development of diabetic retinopathy, and the metabolic memory
346 phenomenon associated with its progression. *Antioxidants Redox Signal*. 2010; 13(6):
347 797–805.
- 348 26. Alghadyan AA. Diabetic retinopathy – An update. *Saudi J Ophthalmol*. 2011; 25(2):
349 99–111.
- 350



A**B**